| Targeting postprandial glucose levels to attain glycemic control in Diabetes |
| HbA (1c) is the gold standard measure of glycaemic control but recent evidence suggests that postmeal hyperglycaemia also plays an important role in the etiology of diabetes-associated complications. |
|
| Health issues in diabetic women – latest information |
| Diabetes has been associated with fertility issues, higher inflammatory stress & has been found to contribute to increased prevalence and incidence of atrial fibrillation… in women. |
|
| Unique benefits of Voglibose in diabetics |
| This article discusses the unique benefits of Voglibose. Voglibose prevents pioglitazone-induced body weight gain in Type 2 diabetic patients, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients & reduces the progression of carotid intima-media thickness. |
| |
| Unique benefits of Voglibose in diabetics |
|
| Voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients |
|
 |
|
The study recruited 31 randomly chosen Type 2 diabetic patients (14 men, 17 women) |
|
|
|
|
|
One group was treated for >3 months with diet alone (control group; n = 17, age 60.2 ± 2.5 years, duration of diabetes 11.7 ± 1.5 years) |
|
|
|
|
|
Other group was treated with diet plus voglibose (0.9 mg daily) (voglibose group; n = 14, age 61.1 ± 3.6 years, duration of diabetes 9.6 ± 1.3 years). |
|
|
|
|
|
Pioglitazone treatment was given to each group at the dose of 15 mg for 3 months. |
|
|
|
|
|
Dosage was increased to 30 mg for the next 9 months. |
|
|
|
|
|
Diet therapy consisted of 104.6 kJ kg–1 of ideal body weight per day. |
|
|
 |
|
| |
| Body weight was examined at the beginning and the end of the study. |
The body weight of the voglibose group prior to voglibose treatment was 72.6 ± 4.5 kg). Body weight increased by 0.1 ± 0.3 kg (0.02%) in the voglibose group and 2.5 ± 0.4 kg (3.7%) in the control group after pioglitazone treatment (Fig 1).
This result suggests that voglibose treatment prevents the body weight gain induced by pioglitazone. Thus, voglibose may be a potentially useful drug for increasing the benefit of pioglitazone treatment by controlling body weight.
Negishi M et al. Br J Clin Pharmacol. 2008 Aug;66(2):318-9. Epub 2008 Apr 30 |
|
 |
|
| |
| Voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients |
|
| 30 obese type 2 diabetic patients were randomly assigned and treated for 3 weeks with either diet alone (the control group) or diet plus voglibose (0.9 mg daily) (the voglibose group) (n=15 each). |
| |
| Analysis of the diurnal metabolic profiles revealed- |
|
|
A significant reduction of postprandial hyperglycaemia and hyperlipidemia in the voglibose group relative to the control group (P<.05) |
|
|
|
|
|
Similar improvement were seen in body mass index and hemoglobin A(1c) in voglibose group and control group |
|
|
|
|
|
Voglibose also decreased significantly the plasma levels of soluble intercellular adhesion molecule 1 and urinary excretion of 8-iso-prostaglandin F (2) alpha and 8 hydroxydeoxyguanosine (P<.01) and C-reactive protein (P<.05) relative to the control group.
Satoh N et al. Metabolism. 2006 Jun;55(6):786-93. |
|
|
|
 |
|
| |
| Voglibose reduces the progression of carotid intima-media thickness |
|
|
|
Open randomized prospective study |
|
|
|
|
|
Voglibose at a dose of 0.4-0.6 mg/day was added on 51 subjects out of 101 type 2 diabetic patients being treated with diet, sulphonylurea (SU) or insulin injections |
|
|
|
|
|
Average (Ave IMT) and maximum intima-media thickness (Max IMT) of their carotid arteries were examined for 3 years. |
|
|
 |
|
| |
| Results: Irrespective of the differences in treatments, addition of voglibose reduced the progression of Ave IMT and Max IMT to -0.024 +/- 0.047 (+/-S.D.) and -0.021 +/- 0.144 mm/year, respectively. Without voglibose, diabetic patients showed significant (P < 0.0001) progression of Ave IMT and Max IMT (0.056 +/- 0.046 and 0.098 +/- 0.122 mm/year, respectively). |
| |
| The administration of voglibose resulted in |
|
|
A significant reduction of hemoglobin A1C (HbA1c) |
|
|
|
|
|
Reduction in total cholesterol |
|
|
|
|
|
Reduction in triglyceride concentrations and |
|
|
|
|
|
An increase in HDL cholesterol concentration. |
|
|
|
 |
|
| |
Multivariate regression analysis showed that administration of voglibose independently reduced the progression of Ave IMT by 0.069 mm/year (P < 0.0001).
Yamasaki Y et al. Diabetes Res Clin Pract. 2005 Mar;67(3):204-10. |
|
| Voglibose reduces the progression of IMT and may be a candidate for an anti-atherosclerotic drug for type 2 diabetic patients. |